BEIJING, Aug.10, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that the Ministry of Health (the "MOH") of the People's Republic of China recently issued clinical guidelines which for the first time include FISH-based molecular cytogenetics tests as one of the tests to be performed for patients of myelodysplastic syndromes ("MDS"), chronic lymphocytic leukemia ("CLL") and chronic myelocytic leukemia ("CML") during their hospitalization.
The guidelines for these hematological malignancies are posted on the website of the MOH (http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3586/201105/51877.htm).
The Company's leukemia BCR/ABL FISH detection kit has been approved by the State Food and Drug Administration (the "SFDA") of the People's Republic of China and the application for the Company's MDS FISH detection kit is being examined by the SFDA.
"We are excited that FISH tests are now included in the clinical guidelines for MDS, CLL and CML," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "Our participation in respective studies conducted by the MOH and the Chinese Medical Association using FISH tests in comparison to other conventional diagnostic tests for certain hematological malignancies have shown positive results for FISH tests. We believe that this is an important consideration for the MOH to include FISH tests in the clinical guidelines for patients of these hematological malignancies during their hospitalization. We expect that FISH tests will be considered to include in the clinical guidelines for other diseases by the MOH with reference to other studies conducted by the MOH and the Chinese Medical Association using FISH tests which so far have shown desirable clinical benefits in comparison to other conventional diagnostic tests."
The studies for bladder cancer, cervical cancer and prenatal disorders conducted by the MOH using FISH tests have been completed. The Company currently participates in the studies for bladder cancer, cervical cancer and miscarriage conducted by the Chinese Medical Association. The Company's bladder cancer FISH detection kit, cervical cancer FISH detection kit, miscarriage FISH analysis kit and SPR-based HPV DNA chip are being used in these studies. There are approximately 30 leading Tier 1 hospitals participating in each study of the Chinese Medical Association.
About China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.
Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. ContactWinnie YamTel: +852-2511-9808Email: IR@chinameditech.com
|SOURCE China Medical Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved